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Abstract 
 
Increasing evidence suggests that common environmental contaminants can act as endocrine 
disrupters in fish. However, current data are biased towards environmental estrogens, highlighting 
the need to elucidate potential pollutant impact on other endocrine axes. Here, we report a high-
throughput assay to identify chemicals interacting with piscine peroxisome proliferator-activated 
receptors (PPARs). Our transactivation assay employs a fish cell line and uses recombinant proteins 
combining the yeast Gal4 DNA-binding domain with the ligand-binding domain of PPARs from 
plaice. Compared to assays with full-length PPARs, this approach circumvents interaction of 
chemicals binding to retinoid X receptors, which form heterodimers with PPAR and many other 
nuclear receptors. Plaice PPARα and PPARβ are activated by fibrate drugs and by phthalate mono-
esters at concentrations similar to those activating the homologous mammalian receptors. In line 
with their assumed role as central transcriptional regulators of energy homostasis, a number of fatty 
acids activate plaice PPARα and PPARβ. In contrast, tributyl tin oxide (TBTO) is a potent 
antagonist of PPARα and PPARβ, showing activity at environmentally relevant concentrations of 
TBTO (1-50 nM). Given the ubiquitous and persistent nature of TBTO, the possibility that chronic 
environmental effects are occurring via disruption of PPAR signalling in fish should be further 
investigated. 
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 1. Introduction 
 
PPARs have critical roles in regulating energy metabolism and particularly lipid  utilization and 
storage (Feige et al., 2006). PPARs are members of the nuclear hormone receptor (NHR) family and 
are encoded by three genes in mammals, PPARα (NR1C1), PPARβ (NR1C2) and PPARγ (NR1C3). 
PPARs act as heterodimers with retinoid X receptors (RXRs) and both RXR agonists and PPAR 
agonists activate transcription of PPAR target genes (Desvergne et al., 2006).  Reflecting their roles 
in lipid homeostasis, natural endogenous activating ligands for PPARs include fatty acids and fatty 
acid metabolites and targets include a broad range of genes involved in lipid and carbohydrate 
metabolism (Hihi et al., 2002). The role of PPARα is hypothesised to be primarily in controlling the 
reversible induction of β-oxidation in specific tissues, especially liver, as a response to changing 
energy requirements and nutritional status. The evidence for this comes most directly from rodents 
where PPARα is expressed in cells with high catabolic rates of fatty acid oxidation such as 
hepatocytes, cardiomyocytes, kidney proximal tubules and intestinal mucosa (Escher et al., 2001). 
PPARα-null mice are incapable of up-regulating fatty acid oxidation during fasting (Kersten et al., 
1999; Leone et al, 1999). In contrast, mammalian PPARγ is considered to play a critical role in fat 
accumulation particularly in adipocytes, and in lipid-accumulating macrophages (Rosen and 
Speigelman, 2001). The role of PPARβ is less well understood, although various studies suggest 
that PPARβ has a role in global control of lipid homeostasis in mammals (Wagner and Wagner, 
2010). Several synthetic PPAR agonists have been discovered and some are in use as drug 
treatments for dyslipidemia associated with coronary heart disease and diabetes (Fievet and Staels, 
2009). 
PPARs can also be activated by binding environmental pollutants. For example, TBTO, the 
main chemical constituent of TBT-based marine antifouling paints, has been shown to bind and 
activate mammalian PPARγ at nM concentrations (Grün et al., 2006;Hiromori et al., 2009) and 
PPARα is activated by phthalate monoesters (Bility et al., 2004). The possibility that environmental 
contaminants interact with human PPARs has led to the hypothesis that some of these chemicals 
could disrupt lipid and energy homeostasis, and might thus be a factor in the increasing prevalence 
of some chronic conditions such as diabetes and obesity (Grün and Blumberg, 2009). In addition, 
there is increasing concern that synthetic PPAR ligands used as pharmaceuticals are entering the 
environment in significant quantity and consequently adversely affecting wildlife (Rosal et al., 
2010). 
Whilst, PPAR-dependent effects are suggested to occur in humans exposed to environmental 
pollutants or pharmaceuticals, little is known about the potential effects of such chemicals on 
PPARs from other vertebrates. Fish species may be particularly susceptible to PPAR disruption 
since they can be continuously exposed in waters which receive effluents and they have similar 
genes and endocrine pathways to mammals. PPARs have been characterized in various fish species, 
and it is apparent that fish possess homologues of mammalian PPAR α, PPARβ and PPAR γ 
(Leaver et al., 2005;Leaver et al., 2007).  
The aim of this study was to assess the effectiveness of several common environmental 
pollutants and discharged pharmaceuticals to activate or inhibit fish PPARs. To achieve this, and to 
exclude RXR mediated effects, we transfected a fish cell line with plaice PPARα, PPARβ and 
PPARγ ligand-binding domains fused to the DNA binding domain of the yeast transcription factor 
Gal4. The results show that, in response to model PPAR ligands, the products of these constructs 
strongly activate a Gal4-driven luciferase reporter gene in co-tranfected fish cells. In comparison, 
environmental pollutants such as the fibrate drugs and monophthlate esters are weak activators of 
fish PPAR α and PPARβ, whilst TBTO strongly antagonises the activity of plaice PPARα and 
PPARβ at nM concentrations. 
 
2. Materials and Methods 
 
2.1 Gal4-PPAR expression constructs 
 
Plaice PPAR α, β and γ, have been described previously (Genbank accession nos; AJ539467.1, 
AJ536468.1 and AJ243956.2, respectively (Leaver et al., 2005)). To obtain recombinant fusion 
proteins in which the Gal4 DNA-binding domain was fused N-terminally to the ligand binding 
domain (LBD) of PPAR proteins (amino acids 153 to 475 for PPARα, 207 to 511 for PPARβ and 
196 to 533 for PPARγ), cDNAs encoding the LBD of the individual receptoirs were amplified by 
PCR, using a proof-reading DNA polymerase (PfuUltraTMFusion IIHS, Stratagene). At the 5’end 
of PCR primers, restriction enzyme recognition sites were added to allow the in-frame subcloning 
of PCR products between the BamHI and KpnI sites of the vector pBIND (Promega), using 
appropriate enzymes.  
 
2.2 Transactivation assay 
 
Fathead minnow (FHM) cells were maintained at 22°C in an atmosphere of 4 % carbon dioxide 
in DMEM containing 4.5 gL-1 glucose and 110 mgL-1 sodium pyruvate and supplemented with 10 
% foetal bovine serum (FBS) (Gibco), 50 UmL-1 penicillin and 50 µgmL-1 streptomycin. Twenty 
four hours prior to transfection 2 × 105 cells were seeded per well of a 96 well black sided, clear 
bottom microtitre plate (Corning). From this point on and throughout the experiments cells were 
maintained in DMEM as above except that directly prior to transfection FBS was replaced with 
10% charcoal/dextran treated, denatured FBS (Perbio).  
In transactivation assays with transiently co-transfected FHM cells, the ligand-dependent 
transcriptional activity of the Gal4-PPAR constructs is assessed with the help of a reporter plasmid  
construct in which the firefly luciferase gene is under the control of a promoter containing UAS 
(upstream activation sequences), which are recognised by Gal4. To control for differences in 
transfection efficiency, a constitutively expressed control reporter construct encoding Renilla 
luciferase was included in transfections. Experimental controls included treatments in which the 
Gal4-PPAR construct was replaced by an empty vector during transfection, as well as cells 
transfected with the apropriate Gal4-PPAR construct and reporters and treated with ethanol carrier 
only. Transfection mixtures contained, per well of a 96-well microtitre plate, 25 ng Gal4-PPAR 
construct (empty vector pBIND in controls), 25 ng Gal4UAS/luc2P-reporter plasmid (pGL4.31, 
Promega), 10 ng hRluc/CMV internal control reporter plasmid (pGL4.75, Promega) and 1.2 µg 
Polyfect transfection reagent (Qiagen), in 80µl of DMEM. Within each experiment, each treatment 
was performed in triplicate. After 24 h, transfection mixes were removed and replaced with media 
containing compounds of interest. Compounds were diluted into DMEM from ethanolic stock 
solutions (5µl per ml), and 75 µl of the dilution was added per well. All fatty acids, pollutants and 
synthetic agonists were obtained from Sigma. Control treatments received ethanol only. Cells were 
incubated for 24 h before assay. Prior to luciferase measurements, media was removed and the cells 
washed twice with 1× PBS. Then cells were lysed by 10 min of incubation with 75 µl per well of 1× 
passive lysis buffer (Promega). Firefly and Renilla luciferase activities were quantified using an 
assay modified from Dyer et al (2000). The firefly luciferase assay solution included 16mM DTT, 
2mM magnesium sulphate, 25mM Tris/phosphoric acid (pH 8.0), 1mM EDTA, 0.5mM ATP 
(Sigma), 100µM Coenzyme A (Sigma) and 190µM beetle luciferin (Promega). To obtain firefly 
luciferase activities, 75µl of firefly luciferase assay solution was added per well containing 75µl of 
cell lysate, and the plate read in a Wallac Victor2 1420 luminometre. To obtain Renilla luciferase 
activities, 75µl per well of Renilla luciferase buffer (0.5 M sodium chloride, 100mM sodium 
phosphate (pH 5.1), 4mM EDTA, 0.33mgmL-1 BSA (Sigma), 0.67mM sodium azide and 1µM 
coelentrazine) was added and the plate read again. We had previously established in optimisation 
experiments that firefly luciferase activities were completely quenched upon addition of Renilla 
luciferase buffer, and that both luciferase light outputs remained constant for up to 30 mins in each 
of the assay conditions. 
To obtain transctivation activities, firefly luciferase activities were divided by Renilla luciferase 
activities to normalise for transfection variability. Data are either shown as raw transactivation 
activities, or expressed as fold-induction compared to the ethanol treatment of the appropriate Gal4-
PPAR construct (induction experiments), or, in antagonist experiments, as the percentage reduction 
in activity compared to activation by PPAR model inducers Wy14643 or GW501516. Data shown 
are the means of at least three independent experiments. 
The effects of treatments on transactivation activity were tested by one-way analyses of 
variance (ANOVA), followed by multiple comparisons using Dunnets post hoc test. In some cases, 
data were log–transformed to increase the homogeneity of variances (tested using F-max test). 
Where appropriate, repeated measures ANOVA was used, matching results of the same transfection. 
With all tests, results were considered significant when the probability value (P) was < 0.05. 
 
3. Results 
 
3.1 Activation of plaice Gal4LBD constructs with PPAR agonists 
 
Native full-length PPARα from plaice (P. platessa) has previously been shown to increase 
transcription of a reporter gene in a transient transfection assay following activation of the receptor 
by the PPARα-specific synthetic ligand, Wy14643 (Leaver et al., 2005). Similarly Atlantic salmon 
(Salmo salar) PPARβ is activated by GW501516, a synthetic ligand developed for its specificity for 
mammalian PPARβ (Leaver et al., 2007). FHM cells transfected with plaice Gal4-PPAR-LBD 
constructs (hereafter referred to as Gal4-PPARα, Gal4-PPARβ and Gal4-PPARγ) and treated with 
these compounds confirmed that the constructs behaved similarly to full-length PPAR receptors in 
terms of activation (Figure 1). Wy14643, induced luciferase luminescence 450-fold with Gal4-
PPARα, but had no effect on Gal4-PPARβ.  GW501516 was an effective activator of the Gal4-
PPARβ and also of Gal4-PPARα constructs, with inductions of over 460-fold and 253-fold, 
respectively. Bromopalmitate has previously been shown to be an activator of PPARβ in Atlantic 
salmon (Leaver et al., 2007) and bromopalmitate induced transactivation of Gal4-PPARβ and Gal4-
PPARα over 400-fold. However, there was no response in cells transfected with the Gal4-PPARγ 
construct and treated with the mammalian PPARγ-specific ligand rosiglitazone, or with any of the 
other synthetic compounds.  
 
3.2 Plaice PPARα and PPARβ are activated by fatty acids 
 
Previously, native PPARα and PPARβ from both sea bream (Sparus aurata) and plaice have 
been shown to respond to fatty acids, suggesting these compounds to be potential endogenous  
  
 
 
 
 
Fig. 1. Transactivation activity of Gal4-PPAR ligand-
binding domain constructs  in response to PPAR 
activators. 
FHM cells were transiently transfected with Gal4-PPAR 
constructs, firefly luciferase reporter plasmid pGL4.31 and an 
internal Renilla luciferase reporter used to correct for 
transfection efficencies ( pGL4.75). After transfection, cells 
were treated (24 h) with 25 µM Wy14643, 10 µM 
GW501516, 25 µM Bromopalmitate, 10 µM Rosiglitazone or 
0.5% ethanol vehicle. Results are expressed as arbitray units 
of firefly luciferase normalised to Renilla luciferase. Data 
represent the mean + SEM from three independent 
experiments. Asterisks indicate whether activities 
significantly differed from those in ethanol-treated cells 
(P<0.01). 
 
activators of piscine PPARs (Leaver et al., 2005). In FHM cells transfected with the Gal4-
PPARα construct all of the tested fatty acids, with the exception of linoleic acid (18:2n-6), 
signficantly induced reporter gene expression. In cells transfected with Gal4-PPARβ (Figure 2) 
there was was no response after oleic (18:1n-9), linoleic (18:2n-6), linolenic (18:3n-3), arachidonic 
(20:4n-6) or docosahexaenoic acid (22:6n-3) treatments, whereas strong responses were observed 
with palmitoleic, γ-linoleic (γ18:2), stearidonic (18:4n-3) and eicosapentenoic acid (20:5n-3). N-
oleoyl ethanolamine (OEA) and N-linoleyl ethanolamine (LEA) were effective agonists of both 
PPARα and PPARβ. None of the fatty acids tested provoked a response with Gal4-PPARγ (data not 
shown).  
 
3.3 Plaice PPARs are activated by human pharmaceuticals and phthalate monoesters 
 
Several pollutants found in the aquatic environments were tested for potential interaction with 
plaice PPARs in the assay with FHM cells transfected with Gal4-PPARα, Gal4-PPARβ, or Gal4-
PPARγ constructs. Tested compounds included TBTO, benzylbutylphthalate and dimethylphthalate, 
and their mono ester metabolites, and several pharmaceutical fibrates. 
The fibrates are a class of pharmaceutical compounds targeting human PPARα and are used to 
correct lipid imbalances. Five of these compounds (gemfibrozil, bezafibrate, ciprofibrate, 
 Fig. 2. Transactivation of PPARα and PPARβ by fatty 
acids and derivatives.  
FHM cells were transfected and treated as described in the 
legend of Figure 1. Treatments included 100 µM palmitoleic 
acid (16-1), oleic acid (18-1), linoleic acid (18-2), gamma 
linoleic acid (γ18-2), linolenic acid (18-3), stearidonic acid 
(18-4), arachidonic acid (20-4), eicosapentenoic acid (20-5), 
docosahexaenoic acid (22-6), oleoylethanolamide (OEA) or 
linoleoylethanolamide (LEA). Data shown are the mean + 
SEM of three independent experiments . Results are 
expressed as the fold increase over ethanol control of 
normalised firefly luciferase activity. Asterisks represent 
statistically significant differences to activities in ethanol 
controls (*, P<0.01).
 
fenofibrate and clofibric acid) were tested with plaice PPARs at concentrations of 10 and 100 
µM. When added to Gal4-PPARα transfected cells both gemfibrozil and ciprofibrate, at 
concentrations of 100µM, were able to increase transcriptional activity of this receptor, increasing 
activity 58-fold and 5.5-fold, respectively (Figure 3). Bezafibrate had no effect on Gal4-PPARα 
activity from plaice. However, when added to Gal4-PPARβ transfected cells at concentrations of 
10µM and 100µM, bezafibrate was able to induce a 2.3-fold and 48-fold induction in transcriptional 
activation respectively (Figure 3). None of the fibrates tested were able to induce the transcriptional 
activity of Gal4-PPARγ from plaice (data not shown).  
 
 
Figure 3. Activation of PPARα or PPARβ by aquatic contaminants.  
FHM cells were transfected and treated as described in the legend of Figure 1. A, effects on PPARα; B, effects on PPARβ. Cells were 
treated with two concentrations per contaminant : Fluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), 
dimethylphthalate (DMP), benzylbutylphthalate (BBP), bisphenol A and deltamethrin were tested at 10 µM (LOW) and 25 µM 
(HIGH). Mono-1-methylhexylphthalate (MMHP), 1-monobenzylbutylphthalate (MBP), gemfibrozil, bezafibrate, ciprofibrate, 
fenofibrate and clofibric acid were tested at 10 µM (LOW) and 100 µM (HIGH). Bis(tributyltin)oxide (TBTO) was tested at 10 nM 
(LOW) and 50 nM (HIGH). Data are the means + SEM of three independent experiments. Results are expressed as the fold increase 
over ethanol control of normalised firefly luciferase activity.  Asterisks represent statistically significant differences to activities in 
ethanol controls (*, P<0.01). 
 The phthalate plasticizers, dimethylphthalate and benzylbutylphthalate, along with their 
mono-ester equivalents, mono-1-methylhexylphthalate and 1-monobenzylphthalate, were also 
tested for their ability to activate piscine PPARs. Neither of the parent phthalate compounds was 
able to activate any of the Gal4-PPARs. In contrast, both mono-1-methylhexyl phthalate and 1-
monobenzyl phthlate were able to significantly induce the transcriptional activities of Gal4-PPARα 
and Gal4-PPARβ at 100 µM. Compared to treatment with an ethanol vehicle, inductions in activity 
by mono-1-methylhexyl phthalate for Gal4-PPARα and Gal4-PPARβ were 16-fold and 2-fold, 
respectively. 1-monobenzyl phthalate induced both Gal4-PPARα and Gal4-PPARβ activity about 2-
fold at 100µM but had no effect at 10µM.  
Fluorooctanesulfonic acid (PFOS) and perfluorooctanoic ( PFOA), used in the manufacture 
of fluoropolymers, and bisphenol A, used in the plastics industry had no effect with any construct. 
Also, the pyrethroid insecticide, deltamethrin, and the antifoulant, TBTO, failed to affect luciferase 
activity in the presence of any of the plaice PPAR constructs. 
 
3.4 TBTO is a potent inhibitor of plaice PPARα and PPARβ 
 
In addition to testing pollutants for agonist activity on fish PPARs, compounds were also 
tested for their ability to inhibit the response of Gal4-PPARα to Wy14643 and that of Gal4-PPARβ 
to GW501506 (Figure 4). No potent activator of fish PPARγ has been identified and so PPARγ was 
omitted from antagonism studies. PFOS, PFOA, dimethylphthalate, benzylbutylphtalate, 
gemfibrozil, bisphenpolA and deltramethrin did not significantly affect induction of Gal4-PPARα or 
Gal4-PPARβ transactivation activity by model inducers. However relatively low concentrations of 
TBTO (50nM) antagonised Gal4-PPARα activation. 
 
 
 
 
Fig. 4. Antagonism of PPARα and PPARβ by aquatic 
contaminants.  
Transfected FHM cells were treated with Wy14643 and 
GW501516 (model activators), respectively, alone or in 
combination with an aquatic contaminant (see the legend of 
Figure 1 for experimental details).  Means + SEM of three 
independent experiments are shown. Data are expressed as 
the percentage of normalised firefly luciferase luminescence, 
with respect to treatment with Wy14643 (25µM) and 
GW501516 (10µM) alone (NO INHIBITOR). Asterisks 
represent statistically significant differences to the treatment 
without inhibitor (*, P<0.05 ). 
  
The effects of TBTO were further assessed over a concentration range (Figure 5). Inhibitory 
effects of TBTO on the stimulation of Gal4-PPARα activity by WY14643 were detectable from the 
lowest concentration tested (1nM). Moreover, in this experiment the highest concentration of TBTO 
(50nM) partially inhibited the activation of Gal4-PPARβ activity by GW501506 (Figure 5). In 
range finding tests, TBTO had shown cell toxic effects at 500 nM (data not shown). To exclude the 
possibility that the apparent antagonistic effects of TBTO on PPAR transactivation were due to non-
specific effects on transcription rather than a specific interaction with PPARs, we tested the effect of 
TBTO on luciferase activities observed in FHM cells transfected with a positive control two hybrid 
construct system ( pBIND ID and pACTmyoD, Promega), which expresses a Gal4-Id fusion protein 
which interacts with an expressed myoD domain fused to a herpes virus VP16 transactivation 
domain. With this system TBTO did not affect luciferase expression (Figure 5) 
 
 
 
 
Fig. 5. Concentration dependent effects of TBTO on 
plaice PPARα and PPARβ. 
FHM cells transfected with either Gal4-PPARα and Gal4-
PPARβ were treated with a model ligand (Wy14643 or 
GW501516, respectively) in combination with various 
concentrations of TBTO (see the legend of figure 1 for 
experimental details). Means + SEM of three independent 
experiments are shown. Data are expressed as the percentage 
of normalised firefly luciferase luminescence observed in 
CONTROL treatments with Wy14643 and GW501516 alone. 
Asterisks represent statistically significant differences to 
treatment with model ligand alone at P<0.05 (*) or P<0.01 
(**). As an external control, cells transfected with pBIND ID 
and pACTmyoD, which results in constitutive luciferase 
expression, were included to test for general effects of TBTO 
on gene expression. 
 
4. Discussion 
 
Assessing the effects of putative ligands or of chemical pollutants on native PPARs is 
complicated by the fact that PPARs are active as heterodimers with RXRs, and RXR ligands also 
activate PPAR-RXR heterodimers (Mukherjee et al., 1998). To enable the study of chemical effects 
on PPAR in the absence of interaction effects with RXR-ligands, we isolated flounder PPAR ligand-
binding domains and fused them to a yeast Gal4 DNA-binding domain. Co-transfection of fish cells 
with cDNAs encoding these fusion proteins together with a luciferase reporter gene driven by a 
promoter containing Gal4 binding sites enabled the measurement of PPAR activation in the absence 
of RXR, with reporter gene expression presumably being mediated by endogenous PPAR-
interacting cellular co-activator proteins. Using this system it was possible to demonstrate strong 
PPARα-driven reporter gene expression in the presence of Wy14643, previously shown to activate 
both mammalian and piscine PPARα/RXR heterodimers. The mammalian PPARβ-specific ligand 
GW501516 activated both flounder PPARα and PPARβ, but maximally only at concentrations 
considerably higher than those activating mammalian PPARβ. GW501506 has an EC50 of 1nm with 
human PPARβ and greater than 1µM for PPARα (Oliver et al., 2001), whereas approximate EC50s 
for plaice PPARβ and PPARα are 1µM and 4µM respectively (data not shown). 
Fatty acids and their derivatives also activated both flounder PPARα and PPARβ, and at 
concentrations similar to those reported in mammals (Göttlicher et al., 1992;Issemann et al., 1993). 
The effects of selected fatty acids were also tested over a range of concentrations. In general for 
most fatty acids and for both Gal4-PPARα and Gal4-PPARβ, luciferase activity was not increased 
below a fatty acid concentration of 60µM, with the exception of γ-linoleic acid which was active 
with Gal4-PPARβ at concentrations above 30µM (data not shown). In line with mammals, a number 
of fatty acids induced transactivation of plaice GAL4-PPARα in this study. The most active fatty 
acid-like compounds were OEA and LEA.OEA is also a potent agonist of mammalian PPARα, and 
appears to have roles in controlling feeding through PPAR interactions  (Schwartz et al., 2008). 
Notably in our study there was a tendency for fatty acids themselves to induce greater activity as the 
degree of unsaturation increased from 16:1 up to 20:5n-3 (eicosapentenoic acid). Docosahexaenoic 
acid (22:6n-3; DHA) was less effective. A previous study on native plaice PPARs indicated that 
DHA activated PPARγ in preference to PPARα and PPARβ (Leaver et al., 2005). However, neither 
plaice Gal4-PPARγ nor Gal4-PPARβ was affected by DHA. DHA has been reported to activate 
mouse RXR (de Urquiza et al., 2000), indicating that in the previous study on fish, DHA may have 
been acting on RXR, the endogenous heterodimeric partner for transfected PPAR. Plaice PPARγ, 
like PPARγ of other fish species, differs in structure from mammalian PPARγ and from all PPARα 
and PPARβ proteins at amino acid residues critical for ligand binding (Leaver et al., 2005;Maglich 
et al., 2003). Importantly, from previous studies and from the experiments reported here, it is 
apparent that fish PPARγ does not have high levels of constitutive activity. In the Gal4 assay, 
reporter gene activity driven by plaice PPARγ was very low and at background levels. The low 
constitutive activity of piscine PPARγ, the high degree of conservation amongst fish species and the 
lack of response to fatty acids or mammalian subtype specific ligands suggests that if endogenous 
and other ligands for piscine PPARγ exist, they are likely to have some significant structural 
differences compared to fatty acids.  
Several environmental pollutants, some of which have been reported to activate mammalian 
PPARs, were also tested with the plaice Gal4-PPAR chimerae. Amongst the compounds tested were 
several of the fibrate drugs, developed as subtype specific agonists of human PPARα.  The presence 
of these fibrate drugs has been reported in sewage treatment effluent and consequently they 
ultimately accumulate in the aquatic environment (Buser and Müller, 1998;Ternes, 1998;Andreozzi 
et al., 2003;Sanderson et al., 2003;Fent et al., 2006). Thus there is some interest in their possible 
effects on fish living in contaminated environments. In humans and rodents clofibrate, gemfibrozil 
and ciprofibrate are an order of magnitude more potent on PPARα than PPARβ or PPARγ, whilst 
bezafibrate is an almost equally effective agonist of all three subtypes (Willson et al., 
2000;Mukherjee et al., 2002). Plaice differ in that bezafibrate is selective for PPARβ which is 
similar to the situation in the African clawed frog (Xenopus laevis), where bezafibrate activates 
PPARβ but has little or no effect on PPARα or PPARγ (Krey et al., 1997). These previous data and 
the results here suggest fibrates to be targets of PPARs in a diverse range of species including 
mammals, fish and amphibians. Our results indicate that at least some of the fibrate drugs present in 
the aquatic environment could exert toxic effects in fish via PPAR mediated pathways, but that the 
concentrations required (>10µM) far exceed measured environmental concentrations of individual 
fibrates, maximum concentrations of which have been reported between 0.02µM and 0.2µM in 
various sewage treatment effluents (Buser and Müller, 1998;Ternes, 1998;Andreozzi et al., 
2003;Sanderson et al., 2003; Kolpin et al., 2002;Stumpf et al., 1999). However, the demonstration 
that multiple fibrates can activate fish PPARs shows that additive effects in the environment should 
be considered. 
Phthalates are compounds used in the manufacturing industry as plasticizers, which serve to 
soften PVC products. In addition they are often found in cosmetics, perfumes, industrial paints and 
solvents and certain drugs, and measured environmental concentrations can be similar to 
concentrations causing laboratory effects in some animals (Oehlmann et al., 2009). Phthalates also 
cause peroxisome proliferation when given to laboratory rodents and are ligands for mammalian 
PPARs, and have consequently been linked to rising levels of obesity and diabetes in exposed 
humans (Desvergne et al., 2009). Both benzylbutylyphthalate and dimethylphthalate failed to 
increase PPAR-driven reporter gene expression at concentrations up to 25µM. However, due to the 
biotransformation process that occurs within organisms, parent phthalate compounds are 
metabolized to their monophthalate esters and therefore two of these transformation products were 
selected for testing in our in vitro assay system. It has previously been reported that mono-1-
methyl-hexyl-pthalate can activate both murine and human PPARα and PPARγ at concentrations 
above 62.5µM (Lampen et al., 2003). In agreement with these findings mono-1-methyl-hexyl-
phthalate proved to be an effective, but not particularly potent, activator of plaice PPARα and also 
of PPARβ. In contrast to mammalian PPARγ, mono-1-methyl-hexyl-phthalate had no effect on 
PPARγ-dependent reporter gene expression. At 100µM, mono-benzyl-phthalate activated plaice 
PPARα and PPARβ isotypes, although only slightly (2-fold). In rodents, mono-benzyl-phthalate is 
an activator of all three PPAR subtypes (Lampen et al., 2003), although with apparently more potent 
effects on PPARα and PPARγ than PPARβ.   
In previous studies on fish PPARs, PFOA has been shown to transactivate PPAR/RXR 
heterodimers (Leaver et al., 2005) and in mice and humans both PFOA and PFOA act as weak 
agonists in a similar Gal4-PPAR assay to that used here (Takacs and Abbott, 2007). However, plaice 
Gal4-PPAR was not affected by PFOA or PFOS, which suggests that, as explained above for DHA, 
these compounds may be targeting RXR in fish. Even in mice the effects of PFOA on PPAR-target 
genes appear to be to some extent independent of PPARα (Rosen et al., 2008), indicating that other 
mechanisms of effect should be investigated. 
We also tested environmental pollutants for inhibition of Wy14643 and GW501516-activated 
plaice PPARα and PPARβ respectively. Most significantly TBTO was found to be inhibitory to both 
plaice PPARα and PPARβ at concentrations as low as 1nM in cellular transfection assays. Recently 
TBTO and its analogs have been found to be potent nM agonists of mammalian and amphibian 
PPARγ and of mammalian and gastropod mollusc RXR (Nishikawa et al., 2004;Hiromori et al., 
2009;Grün et al., 2006). The activation of RXR by TBT may underly the development of imposex 
in wild populations of molluscs (Nishikawa et al., 2004). In mice administration of TBTO at nM 
concentrations in utero causes subsequent increases in fat mass dependent on activation of PPARγ 
(Kirchner et al., 2010). There is no information regarding the effects of TBTO on fish RXR, but the 
potent inhibitory effects on PPARα and PPARβ and a lack of effect on PPARγ show that fish may 
have different responses to low level TBTO than mammals and amphibians. Nevertheless, these 
results suggest that fish inhabiting environments polluted with this compound could be 
metabolically impaired with respect to PPAR signalling. Measured concentrations of TBTO and 
related organotin compounds in the tissues of wild fish are often in the µgKg-1 range (Hoch, 2001; 
Antizar-Ladislao, 2008). For comparison, 10nM, a concentration at which plaice PPARα was 
inhibited, is approximately 6µgL-1.  
In conclusion plaice PPARα and PPARβ exhibit both similarities and differences to their 
mammalian counterparts. Some ligands such as Wy14643, GW501506 and some fibrates act as 
activators of plaice PPARs as they do in mammals, whilst other mammalian ligands are not 
effective in activating fish PPARs. Of the environmental pollutants tested, only TBTO had effects at 
environmentally relevant concentrations. Although environmental concentrations of TBT have been 
decreasing in many parts of the world following legislation to limit their use, they are still 
detectable in sediments and fish tissues in quantities (Antizar-Ladislao, 2008) that would, based on 
the results reported here, inhibit ex vivo piscine PPARα and PPARβ. Given the potency of this 
contaminant and its persistent and ubiquitous presence in estuarine environments, these effects 
should be further studied in vivo, to establish what, if any, are the physiological consequences and 
knock-on ecological effects of exposure.  
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